The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phenotype, cancer risk, and surveillance in Beckwith–Wiedemann syndrome depending on molecular genetic subgroups
Open accessAbstract
Patients with Beckwith–Wiedemann syndrome (BWS) have an increased risk to develop cancer in childhood, especially Wilms tumor and hepatoblastoma. The risk varies depending on the cause of BWS. We obtained clinical and molecular data in our cohort of children with BWS, including tumor occurrences, and correlated phenotype and genotype. We obtained similar data from larger cohorts reported in the literature. Phenotype, genotype and tumor occurrence were available in 229 of our own patients. Minor differences in phenotype existed depending on genotype/epigenotype, similar to earlier studies. By adding patients from the literature, we obtained data on genotype and tumor occurrence of in total 1,971 BWS patients. Tumor risks were highest in the IC1 (H19/IGF2:IG‐DMR) hypermethylation subgroup (28%) and pUPD subgroup (16%) and were lower in the KCNQ1OT1:TSS‐DMR (IC2) subgroup (2.6%), CDKN1C (6.9%) subgroup, and the group in whom no molecular defect was detectable (6.7%). Wilms tumors (median age 24 months) were frequent in the IC1 (24%) and pUPD (7.9%) subgroups. Hepatoblastoma occurred mostly in the pUPD (3.5%) and IC2 (0.7%) subgroups, never in the IC1 and CDKN1C subgroups, and always before 30 months of age. In the CDKN1C subgroup 2.8% of patients developed neuroblastoma. We conclude tumor risks in BWS differ markedly depending on molecular background. We propose a differentiated surveillance protocol, based on tumor risks in the various molecular subgroups causing BWS. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of tumorigenesis in overgrowth syndromes: a comprehensive review
Lapunzina, P. (2005) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30064 · Cited by 276 · cited 1×
“…so the velocity of the tumor growth, the sensitivity, and specificity of the screenings procedure, the interval between the screenings, the treatment schedules of the various stages of the tumor, and the effectiveness of these treatment schedules need to be carefully determined [Lapunzina, 2005].”
Background
Cited by
The Key Role of Epigenetics in Human Disease Prevention and Mitigation
Feinberg, A. P. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1402513 · Cited by 638
Brioude, F., Kalish, J. M., Mussa, A., Foster, A. C., Bliek, J., Ferrero, G. B., Boonen, S. E., Cole, T., Baker, R., Bertoletti, M., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.166 · Cited by 603
Self-citationThe genetic changes of Wilms tumour
Treger, T. D., Chowdhury, T., Pritchard-Jones, K., & Behjati, S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0112-0 · Cited by 257
Metadata
- Authors
- Maas, S. M., Vansenne, F., Kadouch, D. J. M., Ibrahim, A., Bliek, J., Hopman, S., Mannens, M. M., Merks, J. H. M., Maher, E. R., & Hennekam, R. C.
- Venue
- American Journal of Medical Genetics Part A
- Publisher
- Wiley
- Published
- 2016-07-15
- Volume
- 170
- Issue
- 9
- Pages
- 2248-2260
- ISSN
- 1552-4825 (ISSN-L)
- 1552-4833
- OpenAlex
- W2464376411
- Cited by
- 210
- References
- 1
- FWCI
- 17.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phenotype, cancer risk, and surveillance in Beckwith–Wiedemann syndrome depending on molecular genetic subgroups. https://app.cochat.ai/papers/10.1002/ajmg.a.37801
- The paper
- Maas, S. M., Vansenne, F., Kadouch, D. J. M., Ibrahim, A., Bliek, J., Hopman, S., Mannens, M. M., Merks, J. H. M., Maher, E. R., & Hennekam, R. C. (2016). Phenotype, cancer risk, and surveillance in Beckwith–Wiedemann syndrome depending on molecular genetic subgroups. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.37801
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.